Hard-Core Computing To Drive Microbiome-based R&D

Microbiome research is generating huge amounts of data on the presence and proliferation of microbes in the gastrointestinal tract and elsewhere in the body, and the desire to apply this data to the discovery of medicines is shaping a new drug development process, driven as much by mathematics and computational analytical techniques as the use of more conventional methods.

The past four weeks have already seen Microbiotica Ltd., a new UK company spun out of the Wellcome Trust Sanger Institute, wanting to exploit the massive amounts of data...